Practical Guidelines Management of Graves Ophthalmopathy

Imam Subekti, Pradana Soewondo, Suharko Soebardi, Budiman Darmowidjojo, Dante Saksono Harbuwono, Dyah Purnamasari, Tri Juli Edi Tarigan, Wismandari Wisnu, Dicky Levenus Tahapary, Farid Kurniawan, M Sidik, Syntia Nusanti, Salmarezka Dewiputri, Hernawita Suharko, Gusti G Suardana, Indrati Suroyo, Vally Wulani, Alvita Dewi Siswoyo, Soehartati Gondhowiardjo, Henry Kodrat

Abstract


Graves’ ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves’ disease, based on inflammatory and autoimmune conditions in orbital tissue. This practical guideline was formed by a multidiciplinary team, and is intended to provide guidance for diagnosis and management of Graves’ ophthalmopathy in daily clinical practice to improve quality of care and treatment outcome.

Keywords


Graves’ ophthalmopathy; diagnosis; management

References


Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5:9–26.

Kartono D. Korelasi antara ketebalan otot ekstraokular pada CT scan orbita dengan derajat oftalmopati graves. FKUI. Jakarta; 2017.

Subekti I. Diagnosis dan pengelolaan oftalmopati Graves. Jakarta Endocrinology Meeting. Jakarta: Divisi Metabolik Endokrinologi, Departemen Ilmu Penyakit Dalam FKUI/RSCM; 2008. p. 30–5.

Subekti I. Hubungan TSH receptor antibody, thyroid stimulating antibody, dan thyroid blocking antibody dengan aktivitas klinis dan derajat keparahan oftalmopati graves. Fakultas Kedokteran Universitas Indonesia. Jakarta.; 2011.

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343–421.

Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7:167–86.

Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pr. 2011;21(6):593–646.

Bartalena L, Marcocci C, Pinchera A. Treating severe Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab. 1997;11(3):521–36.

Tu X, Dong Y, Zhang H, Su Q. Corticosteroids for Graves’ ophthalmopathy: Systematic review and meta-analysis. 2018;2018.

Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, Single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234– 40.

Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves ’ orbitopathy ( EUGOGO ) on management of GO. Eur J Endocrinol. 2008;158:273–85.

Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5(2):134–42.

Stan MN, Salvi M. Rituximab therapy for Graves’ orbitopathy – lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):R101-9.

Atienza-Mateo B, V.Calvo-Río, Martín-Varillas JL, Demetrio-Pablo R. Anti-IL6-receptor Tocilizumab in Graves orbitopathy. Multicenter study of 29 patients. Sci Abstr. 2018;SAT0601:1153–4.

Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-61.


Full Text: PDF Appendix 1

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Acta Medica Indonesiana